Liu H, Du H, Khabibullin D, Zarei M, Wei K, Freeman G, et al. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun. 2023;14:1214 pubmed publisher

Zhang S, Lee S, Nie L, Huang Y, Zou G, Jung Y, et al. Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis. Cancer Commun (Lond). 2022;: pubmed publisher

Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, et al. mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat Commun. 2020;11:4684 pubmed publisher

Ochocki J, Khare S, Hess M, Ackerman D, Qiu B, Daisak J, et al. Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. Cell Metab. 2018;27:1263-1280.e6 pubmed publisher

Grabiner B, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4:554-63 pubmed publisher